Orthofix (NSDQ:OFIX) today said it entered an exclusive license agreement to commercialize Igea‘s bone, cartilage and soft tissue stimulation products in the U.S. and Canada. Through the agreement, Orthofix has the rights to pursue FDA approvals and commercialization of Italy-based Igea’s platform of orthopedic products. Orthofix will market the products, which will expand its bone […]